275 related articles for article (PubMed ID: 11816442)
1. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
Veeken H; Ritmeijer K; Seaman J; Davidson R
Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
[TBL] [Abstract][Full Text] [Related]
3. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
4. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
Singh S ; Kumar J; Singh R; Dwivedi SN
Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
[TBL] [Abstract][Full Text] [Related]
6. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
8. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
Diro E; Lynen L; Mohammed R; Boelaert M; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2014 May; 8(5):e2875. PubMed ID: 24854196
[TBL] [Abstract][Full Text] [Related]
9. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
Salih MAM; Fakiola M; Lyons PA; Younis BM; Musa AM; Elhassan AM; Anderson D; Syn G; Ibrahim ME; Blackwell JM; Mohamed HS
Parasite Immunol; 2017 Jun; 39(6):. PubMed ID: 28370072
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
[TBL] [Abstract][Full Text] [Related]
13. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
14. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
Rijal S; Chappuis F; Singh R; Bovier PA; Acharya P; Karki BM; Das ML; Desjeux P; Loutan L; Koirala S
Trans R Soc Trop Med Hyg; 2003; 97(3):350-4. PubMed ID: 15228258
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
16. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
Collini P; Premchand N; Lockwood D; Greig J
Ann Trop Med Parasitol; 2009 Jul; 103(5):455-9. PubMed ID: 19583915
[No Abstract] [Full Text] [Related]
17. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
[TBL] [Abstract][Full Text] [Related]
18. Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment.
Osman OF; Oskam L; Zijlstra EE; el-Hassan AM; el-Naeim DA; Kager PA
Trans R Soc Trop Med Hyg; 1998; 92(4):397-400. PubMed ID: 9850390
[TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
[No Abstract] [Full Text] [Related]
20. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]